|本期目录/Table of Contents|

[1]张洁,杨春综述,徐军审校.PPIs对心血管系统的影响及作用机制[J].医学研究与战创伤救治(原医学研究生学报),2017,19(06):625-628.[doi:10.3969/j.issn.1672-271X.2017.06.016]
点击复制

PPIs对心血管系统的影响及作用机制()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第19卷
期数:
2017年06期
页码:
625-628
栏目:
综述
出版日期:
2017-11-23

文章信息/Info

Title:
-
作者:
张洁; 杨春综述; 徐军审校
作者单位： 210002南京,南京军区南京总医院干部心内科
Author(s):
-
关键词:
质子泵抑制剂; H+/K+—ATP酶; 心肌梗死; 心律失常
Keywords:
-
分类号:
R541.7
DOI:
10.3969/j.issn.1672-271X.2017.06.016
文献标志码:
A
摘要:
质子泵抑制剂（PPIs）是目前最有效的抑酸药，也是消化科的常用药。总体来说，PPIs的使用是非常安全的，但长远来看，仍需要重视其潜在风险。阿司匹林或氯吡格雷与PPIs之间的药物相互作用曾是心内科医师非常关注的问题。然而目前，长期单用PPIs制剂对心血管的影响也逐渐引起重视。文章主要综述既往无心脏病史的人群，长期服用PPIs制剂对其心血管系统的风险以及讨论其可能的生物学机制。
Abstract:
-

参考文献/References:

[1]崔俊芳,张亚婷,刘倩楠,等.健康体检人群中幽门螺旋杆菌感染现状的调查及分析[J].东南国防医药,2016,18(5):496-497，510.
[2］李志坤,王福文.药物治疗应激性胃溃疡的研究进展[J].医学研究生学报,2015,28(1):110-112.
[3］Abraham NS. Abraham NS. Proton pump inhibitors: potential adverse effects[J]. Curr Opin Gastroenterol, 2012, 28: 615-620.
[4］Pappas M, Jolly S, Vijan S. Defining appropriate use of protonpump inhibitors among medical inpatients[J].J Gen Intern Med, 2016, 31: 364-371.
[5］Freedberg DE, Yang YX, Abrams JA. Proton pump inhibitors and myocardial infarction[J]. Gastroenterology,2015, 149: 830-833.
[6］Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry[J]. Circulation,2011, 123: 474-482.
[7］Corleto VD, Festa S, Di Giulio E, et al. Proton pump inhibitor therapy and potential long-term harm[J]. Curr Opin Endocrinol Diabetes Obes, 2014, 21: 3-8.
[8］Kashour T, Al-Tannir M, Bahamid R. Changing prescription pattern of omeprazole among patients receiving clopidogrel[J]. Int Heart J, 2014, 55: 93-95.
[9］Melloni C, Washam JB, Jones WS, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coad ministered with dual antiplatelet therapy: systematic review[J]. CircCardiovasc Qual Outcomes, 2015, 8: 47-55.
[10］Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population[J]. PLoS One, 2015,10: e124653.
[11］Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors[J]. Expert Opin Drug Metab Toxicol, 2014, 10: 175-189.
[12］Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine[J]. Circulation, 2013,128: 845-853.
[13］Würtz M, Grove EL. Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions[J]. Ugeskr Laeger, 2013, 175: 2094-2098.
[14］Goodman SG, Clare R, Pieper KS, et al. Association of protonpump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial[J]. Circulation, 2012, 125: 978-986.
[15］Shih CJ, Chen YT, Ou SM, et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction[J]. Int J Cardiol ,2014, 177: 292-297.
[16］Takada K, Ishikawa S, Yokoyama N, et al. Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation[J]. Int Heart J, 2014, 55: 228-233.
[17］Bouziana SD, Tziomalos K. Clinical relevance of clopidogrel-proton pump inhibitors interaction[J]. World J Gastrointest Pharmacol Ther, 2015, 6: 17-21.
[18］El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias[J]. Int J Gen Med, 2013, 6: 515-518.
[19］Wilson AM, Shin DS, Weatherby C, et al. Asymmetric dimethyl arginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease[J]. Vasc Med, 2010, 15: 267-274.
[20］Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy[J]. Ther Clin Risk Manag, 2015,11: 449-467.
[21］Reffelmann T, Ittermann T, Drr M, et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality[J]. Atherosclerosis, 2015, 219: 280-284.
[22］Yang YX, Metz DC.Safety of proton pump inhibitor exposure[J]. Gastroenterology, 2012,139: 1115-1127.
[23］Lu TM, Chung MY, Lin MW, et al. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography[J]. Int J Cadiol, 2011, 153: 135-140.
[24］Cooke JP. DDAH: a target for vascular therapy[J]. Vasc Med,2010,15: 235-238.
[25］Hess MW, Hoenderop JG, Bindels RJ, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition[J]. Aliment Pharmacol Ther, 2012, 36: 405-413.
[26］Turnock M, Pagnoux C, Shore K. Severe hypomagnesemia and electrolyte disturbances induced by proton pump inhibitors[J]. J Dig Dis, 2014, 15: 459-462.

相似文献/References:

[1]龚建明,李以宏,雷军平.氯吡格雷与质子泵抑制剂相互作用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2011,13(05):440.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2017-11-20